About ATNX

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenexs Oncology Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites, human absorption biology and through the application of Athenexs proprietary research and selection processes in the lab. The Companys current clinical pipeline is derived from two different platform technologies Athenex calls Orascovery and Src Kinase Inhibition. The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through which Athenex is able to facilitate oral absorption of traditional cytotoxics, which Athenex believes may offer improved patient tolerability and efficacy as compared to IV administration of the same cytotoxics. The Src Kinase Inhibition platform refers to novel small molecule compounds that have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization during cell division. Athenex believes the combination of these mechanisms of action provides a broader range of anti-cancer activity as compared to either mechanism of action alone.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ATNX is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
FYC First Trust Small Cap Growth AlphaDEX Fund 300.1 M 3.00138E+08 262 262 0.2% 0.002 600 K 600276
BIB ProShares Ultra Nasdaq Biotechnology 263.9 M 2.63946E+08 234 234 0.05% 0.000456194 248 K 248404
UBIO Proshares UltraPro Nasdaq Biotechnology 33.0 M 3.30408E+07 228 228 0.03% 0.000258359 27 K 27194
URTY ProShares UltraPro Russell2000 104.2 M 1.04202E+08 2,017 2017 0.01% 5.98007E-05 20 K 20179
UWM ProShares Ultra Russell2000 182.3 M 1.82294E+08 2,017 2017 0.01% 8.95089E-05 36 K 36204
FAD First Trust Multi Cap Growth AlphaDEX Fund 181.5 M 1.81542E+08 675 675 0.04% 0.0004 73 K 72617
FYX First Trust Small Cap Core AlphaDEX Fund 596.4 M 5.96431E+08 526 526 0.05% 0.0005 298 K 298216
VHT Vanguard Health Care ETF 9.4 B 9.400001E+09 361 361 0.01% 0.00011 1.0 M 1028480
VTWG Vanguard Russell 2000 Growth ETF 286.3 M 2.863E+08 1,245 1245 0.05% 0.00054 155 K 155370
VXF Vanguard Extended Market ETF 6.8 B 6.8E+09 3,242 3242 0.01% 0.00011 782 K 782415
FHLC Fidelity MSCI Health Care Index ETF 1.6 B 1.6E+09 354 354 0.01% 9.57928E-05 153 K 153047
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 2.0 B 2E+09 1,004 1004 0.01% 8.45809E-05 166 K 165633
IBB iShares Nasdaq Biotechnology Index Fund 8.3 B 8.31808E+09 222 222 0.1% 0.001 8.4 M 8398830
ITOT iShares Core S&P Total U.S. Stock Market ETF 18.6 B 1.85536E+10 3,550 3550 0.0% 0 373 K 373133
IWM iShares Russell 2000 ETF 43.0 B 4.29906E+10 2,006 2006 0.03% 0.0003 10.9 M 1.09123E+07
IWO iShares Russell 2000 Growth ETF 9.1 B 9.14116E+09 1,239 1239 0.05% 0.0005 4.5 M 4513260
IWV iShares Russell 3000 ETF 9.8 B 9.77316E+09 2,956 2956 0.0% 0 168 K 167509
LABU Direxion Daily S&P Biotech Bull 3X Shares 657.6 M 6.57565E+08 129 129 0.02% 0.000157771 378 K 377929

Wait, Before You Leave...